Eurand Files for IPO

Eurand NV, a Dutch drug company whose lead product treats exocrine pancreatic insufficiency, has filed for a $152.95 million IPO. It plans to offer seven million ordinary shares at between $17 and $19 per share, and trade on the Nasdaq under ticker symbol EURX. Deutsche Bank Securities and Lehman Brothers are serving as co-lead underwriters. Eurand was formed in 1999, when Warburg Pincus acquired the drug delivery business of American Hone Products Corp. (now Wyeth). It reported 2006 revenue of approximately $109 million.